Description
Roxudo, manufactured by CCL Pharmaceuticals, utilizes the active ingredient Roxadustat to address anemia in patients with chronic kidney disease, whether or not they are on dialysis. Roxadustat works by mimicking the body’s natural response to low oxygen levels (hypoxia). By inhibiting the prolyl hydroxylase (PH) enzyme, it stabilizes hypoxia-inducible factor (HIF), which in turn stimulates the production of endogenous erythropoietin and improves iron transport and absorption. This comprehensive mechanism helps restore healthy hemoglobin levels and improves the overall quality of life for CKD patients.
Effective Oral Therapy As a film-coated tablet, Roxudo 50 mg offers a convenient oral dosing regimen compared to the frequent injections required by older anemia treatments. The 12-tablet packaging is designed for precise clinical management, allowing healthcare providers to monitor patient response and adjust dosages as necessary. Produced by CCL, a trusted name in regional pharmaceuticals, Roxudo represents a significant step forward in providing effective, patient-friendly solutions for the complex management of renal-related anemia.
Reviews
There are no reviews yet.